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Objective: Genomic discoveries should be investigated in generalizable child psychiatric samples in order to justify and inform studies that will
evaluate their use for specific clinical purposes. In youth consecutively referred for neuropsychiatric evaluation, we examined 1) the convergent and
discriminant validity of attention-deficit/hyperactivity disorder (ADHD) polygenic risk scores (PRSs) in relation to DSM-based ADHD phenotypes; 2)
the association of ADHD PRSs with phenotypes beyond ADHD that share its liability and have implications for outcome; and 3) the extent to which
youth with high ADHD PRSs manifest a distinctive clinical profile.
Method: Participants were 433 youth, ages 7–18 years, from the Longitudinal Study of Genetic Influences on Cognition. We used logistic/linear
regression and mixed effects models to examine associations with ADHD-related polygenic variation from the largest ADHD genome-wide association
study to date. We replicated key findings in 5,140 adult patients from a local health system biobank.
Results: Among referred youth, ADHD PRSs were associated with ADHD diagnoses, cross-diagnostic ADHD symptoms and academic impairment
(odds ratios w1.4; R2 values w2%–3%), as well as cross-diagnostic variation in aggression and working memory. In adults, ADHD PRSs were
associated with ADHD and phenotypes beyond the condition that have public health implications. Finally, youth with a high ADHD polygenic burden
showed a more severe clinical profile than youth with a low burden (b coefficients w.2).
Conclusion: Among child and adolescent outpatients, ADHD polygenic risk was associated with ADHD and related phenotypes as well as clinical
severity. These results extend the scientific foundation for studies of ADHD polygenic risk in the clinical setting and highlight directions for further
research.
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964iven progress in the identification of genetic
variants that increase risk for neuropsychiatric
illness,1 determining ways to leverage these dis-coveries in the clinical setting is now a priority for the field
of psychiatric genetics.2 For child psychiatry, this issue is
timely. Attention-deficit/hyperactivity disorder (ADHD) is
one of the most common child-onset conditions.3 Although
twin studies4 have long supported its heritability, a recent
genome-wide association study (GWAS)5 has, for the first
time, implicated specific common variants in its suscepti-
bility, using stringent criteria for significance and replica-
tion. This groundbreaking analysis5 revealed 12 genome-
wide significant loci, several of which highlight molecular
processes not previously considered for ADHD etiology.
Such variants represent the tail of a polygenic component,www.jaacap.orgidentified in prior studies6,7 and now refined, which reflects
the aggregate influence of potentially thousands of small-
effect alleles.
Although the pathophysiology underlying these dis-
coveries is not resolved, this polygenic signal is itself of
clinical interest as an objective index of ADHD suscepti-
bility. Given a lack of biomarkers, child psychiatric di-
agnoses are based on caregiver and teacher ratings and
behavioral observations. While these information sources
show construct validity,8 reports can vary because of setting-
specific behaviors and discrepant standards regarding
age-appropriate variation. Thus, even for experienced cli-
nicians, there can be tension between making an efficient
diagnosis and guarding against overmedicating and over-
labeling children. Furthermore, ADHD is associated with aJournal of the American Academy of Child & Adolescent Psychiatry
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ADHD POLYGENIC RISK IN OUTPATIENTSrange of functional outcomes,3 and childhood symptom
tallies are not useful prognostic indicators.9 Given the
complex genetic architecture of ADHD, the shared liability
between ADHD and other neuropsychiatric conditions,10
and the probabilistic role of susceptibility variants, poly-
genic risk scores (PRSs) are unlikely to yield large magni-
tude improvements in diagnostic efficiency or risk
stratification. Yet, in the absence of other objective in-
dicators, even modest relationships to psychopathology and/
or clinical severity could have value.
Practically, moving from genetic discoveries to patient
care requires intermediate phases of clinical research. As
Green et al.11 note, studies that augment clinical scientific
knowledge are often needed before studies that evaluate the
deployment of genomic information in the clinic, although
these types of clinical studies ultimately become iterative.
For ADHD PRSs, gaps in clinical science require consid-
eration. PRSs based on ADHD GWAS discovery samples
have been related to ADHD diagnosis, dimensional ADHD
symptoms, and learning/educational impairment in inde-
pendent case-control and population-based cohorts
(Table 1). Yet, because ADHD shares liability with other
neuropsychiatric conditions,10 whether ADHD PRSs would
show convergent validity with ADHD-related phenotypes
among referred youths remains an open question. Addi-
tionally, to have clinical value, ADHD PRS/phenotype
associations need not segregate along DSM boundaries, as
long as relationships are reliable. Indeed, as anticipated by
the National Institute of Mental Health Research Domain
Criteria framework,12 genomic discoveries may promote a
more biologically informed psychiatric nosology. As also
shown in Table 1, population and research samples have
related ADHD PRSs to both cognitive and behavioral
phenotypes beyond the conditions that putatively share its
liability. Among these, associations with aggression6 and
working memory (WM)13 are important to confirm in the
outpatient setting because of their implications for
outcome.14-17
To our knowledge, a generalizable child and adolescent
clinical sample suitable for translating emerging genomic
discoveries has not been available. Thus, we have initiated
the Longitudinal Study of Genetic Influences on Cognition
(LOGIC), which ascertains youths consecutively referred
for a neuropsychiatric evaluation. In this article, we used
this cohort to address the following three questions: 1) Do
ADHD PRSs show convergent and discriminant validity
with key ADHD phenotypes in referred youths with a range
of psychopathology? 2) In such a sample, are ADHD PRSs
associated with phenotypes beyond ADHD that share its
liability and relate to functional outcome? 3) Do outpatients
with a high ADHD polygenic burden show a distinctiveJournal of the American Academy of Child & Adolescent Psychiatry
Volume 59 / Number 8 / August 2020clinical profile? We also examined the themes of questions 1
and 2 in adults from the same health care system to provide
a conceptual replication of key questions in patients and to
extend our inquiry to adulthood. Given prior studies, we
expected ADHD PRSs to associate with ADHD and related
phenotypes as well as to clinical severity in youth psychiatric
outpatients. If so, such data would justify and inform
further research leveraging ADHD PRSs as objective risk
indicators and tools for risk stratification in the child psy-
chiatric setting.
METHOD
Subject Recruitment
Participants were youth who were referred to a neuropsy-
chiatric assessment clinic and who agreed to enroll in
research. The clinic, housed within the Psychiatry Depart-
ment of an academic hospital, provides evaluations to assist
with differential diagnosis and/or treatment/educational
planning. The study recruits consecutive referrals before
evaluation. To enroll, youth must provide their clinical data.
They are also asked to provide a DNA sample and sup-
plemental assessments to create a uniform phenotype
battery.
The study is ongoing. Here, we report a planned
analysis of the first wave of genotyped youth. We included
unrelated subjects who were 7–18 years of age; had been
genotyped by the time of the analysis; and were of European
ancestry (based on genomic data), in line with current best
practice given the composition of the discovery GWAS. We
excluded (n ¼ 4) youth with moderate to severe intellectual
disability (mental retardation per DSM-IV, Full Scale
IQ <55). The inclusion criteria were met by 433 unrelated
youth. Their mean age  SD was 11.5  3.1 years, 62.8%
were male, and mean Full Scale IQ  SD was 100.1  14.5
(range, 55–136).
The study was approved by the Partners Healthcare
Institutional Review Board. For youths aged 7–17, parents
provided written informed consent and youth provided
assent. Youth aged 18 provided written consent.
Phenotypes
Psychopathology. Participants received DSM-IV-TR Axis I
diagnoses by or under the supervision of doctoral-level
licensed psychologists who were hospital faculty. See
Supplement 1, available online, for details about this pro-
cess. Diagnoses included the following: ADHD (full n ¼
255, 58.9%; subthreshold n ¼ 68, 15.7%); autistic disorder
(n ¼ 6, 1.4%), Asperger’s syndrome (n ¼ 34, 7.9%),
pervasive developmental disorder not otherwise specified
(NOS) (n ¼ 33, 7.6%); oppositional defiant or conduct
disorder (n¼ 122, 28.2%); bipolar disorder (n¼ 12, 2.8%);www.jaacap.org 965
TABLE 1 Published Studies Examining the Association Between Attention-Deficit/Hyperactivity Disorder (ADHD) Polygenic Risk and ADHD or Phenotypes
Beyond ADHD
Study Sample Type (N)
Discovery
Sample for
ADHD Risk
Score (N)
Phenotypes Associated With ADHD
Polygenic Risk Phenotypes Not
Associated With
ADHD
Polygenic Risk
Additional Details, Implications, and
Comments
ADHD-
Related
Phenotypes
Phenotypes
Beyond ADHD
Hamshere
et al.,
20136
Case-control design
(n [ 452 ADHD vs.
n [ 5,081 controls)
Neale et al.,
201054 (N [
2,064 trios, 896
cases, 2,455
controls)
ADHD dx CD dx and sx;
aggression sx
N/A ADHD PRSs were elevated in ADHD
cases vs. comparisons, higher in
ADHDDCD vs. ADHD without CD, and
associated with comorbid CD
(particularly aggression) sx.
Groen-
Blokhuis
et al.,
201449
Population sample
(Netherlands Twin
Register;
N [ 2,437)
Holmans,
201355—WCPG
(n [ 5,621
ADHD cases,
n [ 13,589
controls)
Maternal rated
ADHD sx at
preschool
and school
age; teacher-
rated ADHD
sx at
school age
N/A N/A ADHD PRSs were associated with
dimensional ADHD sx across different
raters and at 2 developmental periods.
Martin
et al.,
20147
Population sample
(ALSPAC;
N [ 5,661)
UK/Irish ADHD
GWAS (n [ 727
cases and n [
5,081 controls)
Parent-rated
ADHD sx;
INATT and
HYP/IMP sx
PL SC ADHD PRSs were most strongly
associated with total ADHD symptoms
and HYP/IMP sx but also associated
with INATT sx. PRSs were also
associated with 1 of 2 autism-related
traits.
Martin
et al.,
201513
Population sample
(ALSPAC;
N [ 6,832)
UK/Irish ADHD
GWAS (n [ 727
cases and n [
5,081 controls)
Parent-rated
ADHD sx
Latent
neurodevelopmental
factor (including ADHD
sx and PL), IQ, WM
Inhibitory control;
emotion
recognition
ADHD PRSs were associated with IQ and
WM above and beyond associations
with latent neurodevelopmental factor
using structural equation modeling.
Association with IQ was replicated
using a second discovery sample.
Stergiakouli
et al.,
201550
Case-control sample
(n [ 508 vs.
n [ 5,081)
Derived from
ALSPAC
(N [ 4,546)
ADHD case
status; total
ADHD sx
and
INATT sx
N/A Trend-level
association for
HYP/IMP sx in
expected
direction
ADHD PRSs distinguished ADHD dx,
ADHD sx severity but stronger
association with INATT sx than HYP/
IMP sx (opposite pattern to that in
Martin et al., 20147).
Riglin et al.,
20169
Neale et al.,
201054 (N [
Trajectory of
ADHD sx
ADHD-related
neurodevelopmental and
N/A Examined 4 ADHD sx trajectories (low,
intermediate, child-limited, and
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TABLE 1 Continued
Study Sample Type (N)
Discovery
Sample for
ADHD Risk
Score (N)
Phenotypes Associated With ADHD
Polygenic Risk Phenotypes Not
Associated With
ADHD
Polygenic Risk
Additional Details, Implications, and
Comments
ADHD-
Related
Phenotypes
Phenotypes
Beyond ADHD
Population sample
(ALSPAC;
N [ 9,757)
2,064 trios, 896
cases, 2,455
controls)
conduct problems
thought to share liability
with ADHD (called
multimorbidity;
comprising IQ <80, SC,
PL, conduct problems)
persistent). ADHD PRSs were higher in
persistent group vs. other 3).
Multimorbidity was higher in persistent
trajectory and associated with
persistence independent of ADHD
PRSs. After controlling for
multimorbidity, ADHD PRSs were not
associated with sx trajectories/
persistence. Risk scores from SCZ, BPD,
and MDD were not associated with
ADHD trajectories.
Benca et al.,
201730
Unrelated individuals
from population-
based Colorado
twin study
(N [ 386)
Neale et al.,
201054 (N [
2,064 trios, 896
cases, 2,455
controls)
N/A N/A ADHD sx; ADHD
dx; 3 latent EF
variables
(common—
variance from EF
tasks; variance
specific to
updating and
shifting)
No robust findings. Analyses likely
underpowered.
Carey et al.,
201751
College students in
Duke
Neurogenetics
study (N [ 404)
ADHD cases from
PGC cross-
disorder
analysis (N [
1,947 trio cases,
1,947 trio
pseudocontrols,
840 cases, 688
controls)
N/A VS activity Self-reported PA ADHD PRSs were associated with
bilateral VS activity. ASD PRSs used as
controls; were not associated with VS
activity. ADHD PRSs were not directly
associated with PA, but VS activity was
associated. Path model suggested
indirect influence of ADHD PRSs on PA
through VS activity.
Riglin et al.,
201752
Two population
samples (ALSPAC
and NCDS); 1
ADHD clinical
Nine ADHD
studies in
ALSPAC analysis
(n [ 5,621
N/A Parent-reported irritability N/A ADHD PRSs were associated with
irritability in ALSPAC at different ages
and in ADHD clinical sample (higher
OR). ADHD sx also associated with
(continued )
Journalof
the
A
m
erican
A
cad
em
y
of
C
hild
&
A
d
olescent
Psychiatry
w
w
w
.jaacap
.org
967
V
olum
e
59
/
N
um
b
er
8
/
A
ug
ust
2020
A
D
H
D
PO
LYG
EN
IC
RISK
IN
O
U
TPA
TIEN
TS
TABLE 1 Continued
Study Sample Type (N)
Discovery
Sample for
ADHD Risk
Score (N)
Phenotypes Associated With ADHD
Polygenic Risk Phenotypes Not
Associated With
ADHD
Polygenic Risk
Additional Details, Implications, and
Comments
ADHD-
Related
Phenotypes
Phenotypes
Beyond ADHD
sample (SAGE;
N [ 569)
cases, n [
13,589 controls);
SAGE and
NCDS samples
removed for
their analyses
irritability. No evidence of age or sex
differences. MDD PRSs were not
associated with irritability.
Stergiakouli
et al.,
201739
Population-based
(ALSPAC; n [
8,365 children and
n [ 8,340 mothers)
UK/Irish ADHD
GWAS (n [ 727
ADHD cases
and n [ 5,081
controls)
N/A Academic performance/
educational outcomes
and IQ
N/A In youths and mothers, ADHD PRSs were
associated with educational outcomes
and IQ. In youths, influence of ADHD
PRSs on educational outcomes was
mediated substantially by IQ and
partially by ADHD sx.
Du Rietz
et al.,
201753
UK biobank; adult
community/
population sample
40e73 (N [
135,726)
PGC-iPSYCH
ADHD meta-
analysis (n [
20,183 cases
and n [ 35,191
controls)5
N/A ADHD-related: BMI,
neuroticism, DEP, ANX
(suggestive), risk taking,
ALC (intake and DEP),
smoking, V-N reasoning,
neuroticism items
(including irritability and
mood swings); control
traits: age
SCZ or BPD. Seven
of eight control
traits (height, year
of assessment,
menstruation
during
assessment, grip
strength, visual
acuity, self-
reported cancers,
sex of baby)
ADHD PRSs were associated with a range
of conditions likely related to ADHD
liability; controls for dx group analyses
were individuals with no dx. Could not
address ADHD (or ODD, CD, ASD)
because of low rates in sample. No sex-
specific effects. Seven of eight control
traits showed no association.
Nigg et al.,
201840
Case-control
community
volunteer children
aged 7e11 (n [
656; primary model
n [ 337 ADHD
and 177
non-ADHD)
PGC-iPSYCH
ADHD meta-
analysis (n [
20,183 cases
and n [ 35,191
controls)5
ADHD dx;
parent and
teacher
ADHD sx
Two of 5 latent cognitive
constructs (WM and V/A)
Three of 5 latent
cognitive
constructs (trend-
level associations
with MC and PS;
no association
with INHIB)
ADHD PRSs were associated with ADHD
dx, parent- and teacher-rated
dimensional sx, WM and V/A, after
medication washout. In models, WM
and V/A partially mediated association
between WM and V/A and ADHD (dx
and dimensions).
Brikell et al.,
201838
N [ 13,457 children
aged either 9 or 12
from CATSS
PGC-iPSYCH
ADHD meta-
analysis (n [
Parent-rated
ADHD sx
Parent-rated
neurodevelopmental,
Parent-rated
anxiety sx
ADHD PRSs were associated with ADHD
sx, as well as neurodevelopmental,
externalizing, and depression sx.
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ADHD POLYGENIC RISK IN OUTPATIENTSmajor depressive disorder (n ¼ 38, 8.8%), dysthymic dis-
order (n ¼ 2, 0.5%), mood disorder NOS (n ¼ 48, 11.1%);
panic disorder (n ¼ 3, 0.7%), obsessive-compulsive disorder
(n ¼ 11, 2.5%), generalized anxiety disorder (n ¼ 34,
7.9%), anxiety disorder NOS (n ¼ 96, 22.2%); schizo-
phrenia (SCZ)/schizoaffective disorder (n ¼ 1, 0.2%), psy-
chotic disorder NOS (n ¼ 12, 2.8%); intellectual disability
(n ¼ 6, 1.4%). Additionally, 16.9% of referred youths did
not meet criteria for a full Axis I diagnosis, despite having
symptoms. Rates surpassed 100% owing to comorbidity.
Numbers of conditions per patient were 0 (16.9%), 1
(34.6%), 2 (26.1%), and 3 (22.4%).
Parent ratings of dimensional psychopathology symp-
toms were selected a priori for use in subsequent analyses.
Measures (with Cronbach a) included the following: Child
Behavior Checklist (CBCL)/6–18: Attention Deficit Hy-
peractivity Problems (.84), Aggressive Behavior (.94), So-
matic Complaints (.78), and Anxiety Problems (.72); Child
Symptom Inventory (CSI)-IV18: Inattention (.92), Hyper-
activity/Impulsivity (.92), and Depression (.86); Child
Mania Rating Scale (CMRS)19: mania (.73) and irritability
(.82) symptoms; and Social Responsiveness Scale20: Social
Communication/ Interaction (.85) and Social Cognition
(.80). We used parent ratings because they have been shown
to have higher heritability than youth self-reports (which
may have lower reliability and thus more error variance).21
Cognition and Academic Achievement. Children
completed psychometric tests, which were administered
using published instructions. Full Scale IQ and WM were
operationalized via index scores from the Wechsler Intelli-
gence Scale for Children–Fourth Edition22 for youth aged
7–16 and the Wechsler Adult Intelligence Scale–Fourth
Edition23 for youth aged 17–18. Academic achievement
was examined using Word Reading and Numerical Oper-
ations of the Wechsler Individual Achievement Test–Third
Edition (WIAT-III).24
Other Sample Characteristics
No constraints regarding prior treatment were placed on
enrollment, with 59.7% of participants having received prior
psychotherapy and/or psychotropic medications. Parent re-
ports (Table S1, available online) were used to create a binary
medication use variable. Within the sample, 42.7% of par-
ticipants were taking 1 psychotropic medication (23.3%
stimulants).
Genotyping and Polygenic Risk Scores
DNA was collected via blood venipuncture or by Oragene
saliva kits (DNA Genotek, Ottawa, Ontario, Canada) and
was extracted at the Broad Institute of MIT and Harvard.
Using the Infinium PsychChip v1.0 Psych array (Illumina,www.jaacap.org 969
VUIJK et al.San Diego, California), we genotyped all youths with DNA
available at the time. We used standard filters and quality
control procedures (detailed in Supplement 1, available on-
line). Principal component analysis including individuals in
the 1000 Genomes Project25 was used to exclude individuals
of non-European ancestry. Principal component analysis of
the remaining individuals was used to derive covariates
reflecting residual population stratification. Risk scores were
calculated with PLINK26 using the most recently available
GWAS for ADHD,5 SCZ,27 and autism spectrum disorder
(ASD).28 Scores were generated for 12 p value thresholds
from the discovery samples. The most stringent thresholds
include single nucleotide polymorphisms (SNPs) with the
strongest relationship to the diagnosis in the discovery meta-
analysis, with more relaxed thresholds incorporating
increasing numbers of risk-conferring SNPs. PRSs were
standardized within the cohort. See Table S2, available online,
for numbers of SNPs at each threshold for ADHD, SCZ, and
ASD PRSs. For ADHD and ASD, given low numbers of
SNPs, PRSs based on the top two and three thresholds,
respectively, were not analyzed.
Analytic Approach: Youth Sample
For ADHD, we examined scores based on the 10 remaining
p value thresholds, as there is no precedent in the literature
for selecting a single threshold in a heterogeneous clinical
cohort and because true relationships would likely yield
associations across thresholds.29 As PRSs from different
thresholds were correlated (Table S3, available online), we
addressed multiple comparisons in two ways. First, we used
permutation testing based on 10,000 randomly shuffled
data sets to generate a null distribution of the sample test
statistic.30 For questions 1 and 2, we also used a Bonferroni-
corrected a to correct for multiple outcomes.
Questions 1 and 2. Regarding convergent validity, we
examined the association between ADHD PRSs and DSM-
based ADHD phenotypes (diagnoses, ADHD dimensional
symptoms, and academic performance in reading and math).
We selected the CBCL ADH scale to represent dimensional
ADHD symptoms owing to its prior evidence of heritability31
and given our interest in a dimensional representation of the
ADHD construct overall. To establish discriminant validity,
we first related ADHD PRSs to two traits (ie, somatic com-
plaints and social cognition) that were not expected to be
associated with ADHD based on factor-analytic phenotype
studies32 and a prior ADHD PRS analysis,7 respectively. We
then related PRSs for SCZ and ASD to ADHD status and
ADHD symptoms. Regarding associations beyond DSM-
defined ADHD, we related the ADHD PRS to the CBCL
Aggressive Behavior scale and the Wechsler WM index.970 www.jaacap.orgWe used hierarchical logistic regression for the
dichotomous ADHD diagnosis and hierarchical linear
regression for dimensional traits. In step 1, we controlled
for age, sex, and the first five principal ancestry compo-
nents. For WM and achievement, we also controlled for
medication use, given that medications could impact test
performance. Because nonstimulant medications can be
prescribed for ADHD and because patients are not al-
ways aware of the symptoms their medications are
intended to address, we controlled for any medication
use. In step 2, we entered the ADHD PRS. For the lo-
gistic regression, model significance was determined by
Wald’s c2 test, and an odds ratio (OR) reflected the ef-
fect size. For the linear regressions, model significance
was determined by an F test and R2 values, and b co-
efficients reflect effect sizes. For question 1, our
Bonferroni-corrected threshold was .0083 (.05/6 out-
comes, reflecting the dichotomous ADHD diagnosis and
the five dimensions hypothesized to be associated with
risk scores [ie working memory, word reading, numerical
operations, ADHD symptoms, and aggression]). Sensi-
tivity analyses were conducted in all significant analyses
by determining whether associations remained after
controlling for (broad) ADHD.
Question 3. We used multivariate mixed modeling to
determine whether the profile of scores across key psy-
chopathology domains differed in youths with a low
(bottom 30%), medium (middle 40%), and high (top
30%) ADHD polygenic burden. Eight domains (ie,
inattention, hyperactivity, aggression, irritability, mania,
social communication/interaction, depression, and anxi-
ety) were standardized based on the mean and SD of the
current sample. Models sought to determine a main effect
for risk group (ie, whether the overall severity of the
symptom profile differed based on polygenic burden) as
well as an interaction between risk group and psychopa-
thology domain (ie, whether the severity of particular
symptom domains differed as a function of polygenic
burden).
Mixed effects modeling is an extension of regular
regression that is appropriate when data are hierarchically
structured (eg, psychopathology scores within individuals).
The technique does not require the data to be balanced,
presuming data are missing at random.33 Although we
could not confirm that data were missing completely at
random given Little’s MCAR test (c2 (76) ¼ 104.93, p ¼
.02), covariate-dependent missingness in relation to age and
sex did yield a satisfying test statistic (c2 (228) ¼ 213.75,
p ¼ .74), indicating that mixed modeling was appropriate
with age and sex as covariates.Journal of the American Academy of Child & Adolescent Psychiatry
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ADHD POLYGENIC RISK IN OUTPATIENTSBiobank Replication
We used data on patients from the same hospital’s biobank
to conceptually replicate and extend our findings. The
biobank enrolls adults from the Partners Healthcare system
on a continuous basis.34 At the time of analysis, genotyping
had been completed in three waves using the Multi-Ethnic
Global Array (MEGA) (Illumina). Preparation of genomic
data, including standard quality control, data cleaning, and
ancestry determination, has been described elsewhere.35 All
available individuals determined to be of European ancestry
whose samples passed quality control were eligible (N ¼
11,075). Given the potential for extreme generational dif-
ferences in diagnoses, we excluded adults aged >60 years.
Our final sample included 5,140 individuals aged 19–60
years. Calculation of ADHD PRSs was based on the same
summary statistics as our youth sample (ie, same discovery
GWAS5 and same 10 p value thresholds). Linkage-
disequilibrium pruning of the SNP list was done by
applying the clump function from PLINK 1.9, with a 250-
kb window and a minimum r2 that was set at 0.2.
We obtained diagnoses and demographics from elec-
tronic health records. First, we compared patients with
ADHD (ICD-10 code F90) with all other patients. Sec-
ondary analyses compared patients with ADHD only with
patients with mental, behavioral, and neurodevelopmental
disorders (ICD-10 codes F1–F98 excluding F90).
Regarding educational attainment, we dichotomized
adults who had and had not completed college by age 23
years. This age cutoff was used to capture participants who
worked or took a gap year between high school and col-
lege. Additionally, we examined ADHD PRSs in relation
to the presence or absence of a substance use disorder
(SUD) history (ICD-10 codes F10–F19), given associa-
tions of SUDs with ADHD liability36 and public health
outcomes.37
We used logistic regression to examine whether ADHD
PRS was associated with an elevated relative risk for the
three outcomes. We controlled for age, sex, the first five
ancestry components, and biobank genotyping wave. As in
youths, we used permutation testing to generate the null
distribution of the test statistic from the sample. We used a
Bonferroni-corrected a of .0167 (.05/3 tests). For outcomes
other than ADHD, we ran sensitivity analyses controlling
for ADHD status.
RESULTS
Question 1. Convergent and Discriminant Validity of
ADHD PRSs
Among referred youth, multinomial logistic regression of
the ADHD diagnosis variable (full, subthreshold, and none)
showed that variation in ADHD PRSs distinguishedJournal of the American Academy of Child & Adolescent Psychiatry
Volume 59 / Number 8 / August 2020between levels of the diagnosis at eight discovery sample
thresholds. These results were driven by significant differ-
ences between youth with full diagnoses and no diagnoses of
ADHD, whereas only the most stringent threshold differed
between full and subthreshold ADHD (Table S4, available
online). Therefore, we collapsed full and subthreshold
ADHD diagnoses into one category for subsequent ana-
lyses. As shown in Table 2, ADHD PRSs were associated
with this broad ADHD diagnosis at six discovery sample
thresholds after correction for multiple testing, with sig-
nificant ORs between 1.35 and 1.42. Thus, among referred
youths, every increase of 1.0 SD in these PRSs increased the
odds of a diagnosis on the ADHD spectrum 1.4-fold.
ADHD PRS was also significantly associated with
dimensional ADHD symptoms at the three most stringent
discovery sample thresholds (R2 values, 1.84%–2.93%)
(Table S5, available online). Secondary analyses of indi-
vidual ADHD symptom dimensions were conducted using
the CSI, as this measure includes scales representing both of
the core DSM symptom domains of inattention and hy-
peractivity/impulsivity. Results (Table S5, available online)
were consistent with some,7,38 but not all,39 prior studies
(Table 1) that addressed this issue, in that they suggest a
relationship with hyperactivity/impulsivity rather than
inattention symptoms.
Variation in ADHD PRSs was also associated with lower
academic achievement (Table 3). For word reading, four
significant associations were found at inclusive p value
thresholds (R2 values, 1.88%–2.05%). For numerical opera-
tions, three significant associations were found (R2 values,
1.94%–2.27%). Controlling for ADHD did not reduce the
number of significant findings for reading, and one significant
threshold remained for math achievement (Table S6, available
online). Controlling for stimulants instead of any medication
did not change the pattern of findings (data not shown).
Regarding discriminant validity, first we analyzed as-
sociations between ADHD PRSs and traits that were not
expected to be associated with ADHD. As shown in
Table S7 (available online), no significant associations or
pattern of trend-level findings emerged for somatic com-
plaints or social cognition. We then examined SCZ PRSs
(Table S8, available online) and ASD PRSs (Table S9,
available online) in relation to ADHD status and ADHD
symptoms. No significant associations were found for either
SCZ PRSs or ASD PRSs.
Question 2. Association of ADHD PRSs With Phenotypes
Beyond ADHD
ADHD PRSs were also associated with aggression and WM
across diagnoses (Table 4). For aggression, significant as-
sociations were found at the three most stringent p valuewww.jaacap.org 971
TABLE 2 Association of Attention-Deficit/Hyperactivity Disorder (ADHD) Polygenic Risk Score (PRS) in Referred Youth With
ADHD Diagnosis, Controlling for Age, Sex, and Ancestry Components
Discovery Threshold
ADHD Spectrum (n ¼ 323) vs. All Others in Clinical Cohort (n ¼ 110)
OR 95% CI Pseudo R2 Wald c21 Permuted p
p < 1.0 3 10L6 1.40 1.11e1.77 1.73 8.22 .0032
p < 1.0 3 10L5 1.38 1.09e1.74 1.52 7.23 .0050
p < 1.0 3 10L4 1.26 1.01e1.58 0.84 4.02 .0397
p < .001 1.26 1.01e1.58 0.85 4.06 .0408
p < .01 1.44 1.14e1.81 2.01 9.43 .0011
p < .05 1.31 1.05e1.64 1.15 5.56 .0165
p < .1 1.35 1.08e1.69 1.45 6.98 .0078
p < .3 1.33 1.07e1.67 1.31 6.33 .0119
p < .5 1.39 1.11e1.74 1.71 8.18 .0034
p < 1 1.42 1.13e1.78 1.90 9.07 .0019
Note: Boldface type indicates statistically significant findings after correction. Bonferroni corrected critical value ¼ .008. OR ¼ odds ratio; PRS ¼
Polygenic Risk Score.
VUIJK et al.thresholds (R2 values, 1.90%–2.59%). For WM, three sig-
nificant associations were found (R2 values, 2.26%–2.47%),
though at the three most inclusive thresholds. Significant
associations remained for aggression at two of the three sig-
nificant thresholds after controlling for ADHD status, with
slightly less explained variance (R2 values, 1.36%–1.99%).
Associations with WM were unaffected (Table S6, available
online). As with academic achievement, controlling for
stimulants instead of all medications did not change results.
Biobank Replication
As shown in Table S10 (available online), ADHD PRSs
were associated with ADHD diagnoses in adults. At the six
most inclusive thresholds, a 1 SD increase in ADHD PRSs
resulted in a 1.2-fold increase in the odds of having ADHDTABLE 3 Association of Attention-Deficit/Hyperactivity Disorder
Academic Achievement, Controlling for Age, Sex, Medication Us
ADHD PRS Threshold
Word Reading (n ¼ 393)
b R2 (%) F Per
p < 1.0 3 10L6 1.90 1.58 6.64
p < 1.0 3 10L5 1.05 .47 1.96
p < 1.0 3 10L4 .27 .03 0.13
p < .001 .64 .19 0.77
p < .01 L1.01 .47 1.94
p < .05 L2.11 2.05 8.68
p < .1 L2.04 1.99 8.42
p < .3 L1.96 1.77 7.48
p < .5 L2.01 1.88 7.94
p < 1 L2.04 1.92 8.09
Note: Boldface type indicates statistically significant findings after correction
972 www.jaacap.orgversus no ADHD. In a secondary analysis (also Table S10,
available online), we found significant ORs of similar
magnitude at the four most inclusive thresholds when pa-
tients with non-ADHD neuropsychiatric diagnoses were the
reference group, further supporting ADHD PRS convergent
validity in patients.
ADHD PRSs were also associated with educational
attainment at all but one discovery sample threshold, with
greater ADHD risk reducing the likelihood of college
completion (ORs, 1.13–1.23) (Table S11, available online).
Finally, ADHD PRSs were associated with an increased risk
for SUDs at all discovery sample thresholds, with modest
ORs (1.10–1.18) (Table S12, available online). Controlling
for ADHD status did not change these two results in a
meaningful way (Table S13, available online).(ADHD) Polygenic Risk Score (PRS) in Referred Youth With
e, and Ancestry Components
Numerical Operations (n ¼ 398)
muted p b R2 (%) F Permuted p
.0129 .49 .11 0.45 .5021
.1791 .06 .00 0.01 .9368
.7186 L.23 .02 0.10 .7512
.3966 L.03 .00 0.00 .9706
.1807 L1.04 .52 2.06 .1451
.0043 L1.88 1.67 6.74 .0101
.0051 L1.82 1.61 6.52 .0112
.0084 L2.03 1.94 7.87 .0061
.0066 L2.11 2.12 8.60 .0042
.0057 L2.20 2.27 9.25 .0030
. Bonferroni corrected critical value ¼ .0083.
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TABLE 4 Association of Attention-Deficit/Hyperactivity Disorder (ADHD) Polygenic Risk Score (PRS) in Referred Youth With
Traits Beyond ADHD, Controlling for Age, Sex, and Ancestry Components
ADHD PRS Threshold
Aggressive Behavior (n ¼ 394) Working Memory Indexa (n ¼ 394)
b R2 (%) F Permuted p b R2 (%) F Permuted p
p < 1.0 3 10L6 1.35 1.90 7.66 .0082 .94 .42 1.69 .1982
p < 1.0 3 10L5 1.58 2.59 10.52 .0019 .11 .01 0.02 .8889
p < 1.0 3 10L4 1.49 2.40 9.70 .0020 L.09 .00 0.02 .9003
p < .001 .94 .99 3.97 .0471 L.29 .04 0.18 .6737
p < .01 .83 .77 3.05 .0823 L1.01 .54 2.18 .1468
p < .05 .31 .11 0.42 .5145 L1.69 1.47 5.97 .0162
p < .1 .41 .19 0.77 .3760 L1.76 1.64 6.66 .0113
p < .3 .44 .21 0.84 .3573 L2.17 2.47 10.10 .0016
p < .5 .23 .06 0.24 .6226 L2.08 2.26 9.23 .0030
p < 1 .19 .04 0.17 .6847 L2.10 2.33 9.53 .0025
Note: Boldface type indicates statistically significant findings after correction.
aAlso controlled for medication use; Bonferroni corrected critical value ¼ .0083.
ADHD POLYGENIC RISK IN OUTPATIENTSQuestion 3. Multivariate Clinical Profile in Youths With a
High ADHD Polygenic Burden
Based on the three most stringent discovery thresholds,
youth with a high ADHD polygenic burden, on average,
manifested a distinctive clinical profile compared with
youths with a medium or low burden (Table S14, available
online). Significant results were driven by a main effect of
risk group; youths in the high polygenic burden group had a
more severe multivariate pattern of psychopathology
symptoms compared with youths in the low-risk group (b
values ¼ .21–.24, p .014). No significant differences were
found between the medium-risk and low-risk groups.
Figure 1 illustrates the results at the most inclusive
significant threshold (p < 1.0  104). Although analyses
did not yield a significant interaction between domain and
risk group, this question may benefit from a larger sample
with greater power to detect interactions. Post hoc contrasts
suggested that youths with a high ADHD polygenic burden
showed impairment on hyperactivity/impulsivity and
aggression symptoms rather than all domains (hyperactivity:
high versus low risk b ¼ .34, t ¼ 2.74, p ¼ .01, high versus
medium b ¼ .29, t ¼ 2.50, p ¼ .01; aggression: high versus
low risk b ¼ .33, t ¼ 2.57, p ¼ .01, high versus medium
b ¼ .26, t ¼ 2.14, p ¼ .03).DISCUSSION
This study provides what, to our knowledge, is the first
translation of ADHD PRSs to a generalizable child and
adolescent outpatient cohort. Results support the conver-
gent and discriminant validity of ADHD PRSs with
ADHD-related clinical phenotypes among youths referred
for neuropsychiatric evaluation. Conceptual replication inJournal of the American Academy of Child & Adolescent Psychiatry
Volume 59 / Number 8 / August 2020adults confirmed a relationship with clinical ADHD di-
agnoses even versus other neuropsychiatric conditions. In
youths and adults, ADHD PRSs were also associated with
phenotypes beyond the DSM-defined ADHD construct
(including WM and aggression in youths and SUDs in
adults) that share its liability and have implications for
outcome. Finally, youth with a high ADHD polygenic
burden manifested a more severe clinical profile compared
with youths with a lower burden. These findings justify and
inform further studies aiming to leverage ADHD PRSs in
child psychiatric practice.
ADHD PRSs in these analyses reflect the common
genetic variation that collectively distinguished ADHD
cases from non-ADHD controls in a GWAS of approxi-
mately 55,000 individuals.5 Although the biology under-
lying these small perturbations in molecular processes is not
yet resolved, PRSs are unique among potential information
sources in their ability to index this heritable liability. Our
results demonstrate that variation in these risk scores tracks
with the ADHD construct, broadly conceived, among
youth outpatients with a range of psychopathology.
Increasing ADHD polygenic burden was associated with
increased odds of being diagnosed with full or subthreshold
ADHD versus not receiving these diagnoses. Across pa-
tients, variation in ADHD PRSs also related to variation in
ADHD symptoms and in academic impairment. Moreover,
associations in outpatient youth were not indiscriminate.
We found no relationship between ADHD PRSs and two
traits not expected to be associated with ADHD (somati-
zation and social cognition). A degree of specificity was also
documented through lack of associations between SCZ and
ASD PRSs with core ADHD phenotypes. Nonetheless,
relationships emerged with cognitive (WM) and behavioralwww.jaacap.org 973
FIGURE 1 High and Low Levels of Attention-Deficit/Hyperactivity Disorder (ADHD) Polygenic Risk Are Characterized by
Different Psychopathology Symptom Profiles in Referred Youth
Note:Mixed-effects modeling (based on discovery sample threshold p < 1.0  104). Results demonstrate a main effect for risk group, reflecting a significantly more severe
psychopathology profile in youth with high ADHD polygenic risk compared with low-risk group. PRS ¼ polygenic risk score. Please note color figures are available online.
VUIJK et al.(aggression) phenotypes that lie outside the diagnostic
boundaries of ADHD but that have been tied to ADHD
liability in prior studies.6,40
Analyses in adults conceptually replicated these find-
ings. Our adult sample derived from the same catchment
area as our youth cohort and similarly examined real-world
clinical diagnoses, which are relevant to clinical translation.
In adult patients, ADHD PRSs were associated with having
an ADHD diagnosis, even versus having another neuro-
psychiatric condition. Results in adults also substantiated
the relationship between ADHD PRSs and educational
impairment, extending implications beyond grade school
achievement to educational attainment in adulthood.
Finally, in adults, ADHD PRSs were associated with SUD,
which typically has onset later than the age of our youth
sample and was not present in that cohort but which has a
putative relationship to ADHD risk.36
For genomic information to have clinical utility as an
objective risk indicator, precise tracking with DSM di-
agnoses is not necessary. Eventually, risk scores are expected
to be refined to reflect more specific biological processes
with implications for treatment, and these may link to a
range of potential outcomes.41 Nonetheless, PRSs from
DSM-based GWASs represent a useful anchor, as major
categories of illness will likely contribute to the organizing974 www.jaacap.orgprinciples of this evolving framework, given some specificity
in the genomics and psychopharmacologic literatures.41
While the precision of PRS will increase with larger
GWAS samples, our data raise the possibility that even the
small-magnitude relationships found in our cohort could
contribute to earlier and more efficient diagnosis and/or
prompt consideration of treatments with benefits for
ADHD. This possibility requires direct evaluation of PRSs
in clinical trials as well as further clinical science. Regarding
the latter, how exactly genomic risk scores should be cali-
brated must be determined and may benefit from examples
in other medical fields (eg, see Khera et al.42). Capitalizing on
ADHD PRSs as objective indicators will also require mapping
phenotypic associations beyond those examined in this article,
including traits relevant to mood disorders that partially share
genetic risk with ADHD.10 Furthermore, the possibility that
PRSs based on different GWAS thresholds (ie, different
subgroups of ADHD-related variants) may relate to particular
phenotypes should be considered, given that aggression and
cognitive/academic skills in our sample were associated with
PRS at different discovery sample cutoffs.
Finally, our data extend the empirical justification for
evaluating ADHD PRSs as tools for clinical risk stratifica-
tion. In the literature, impaired executive cognition has
been associated with academic difficulties14,15 and reducedJournal of the American Academy of Child & Adolescent Psychiatry
Volume 59 / Number 8 / August 2020
ADHD POLYGENIC RISK IN OUTPATIENTSoccupational attainment15 over and above ADHD. Addi-
tionally, co-occurring aggression can create long-term psy-
chosocial disruption.16,17 In our youth cohort, variation in
ADHD PRSs was associated with variation in these traits,
highlighting possible means by which high ADHD PRSs
could relate to particular patient outcomes. We also exam-
ined the implications of a high ADHD PRS directly in
relation to psychopathology symptom profiles. For several
discovery sample thresholds, referred youth with high
ADHD polygenic burden manifested a more severe clinical
profile. A nonsignificant interaction term prevented us from
concluding that there was a relationship to particular
symptom domains rather than generally increased severity;
however, post hoc tests suggested that youths in the high-
risk group had increased hyperactivity/impulsivity and
aggression. Thus, the possibility that high ADHD PRSs
relate to a particular symptom profile should be examined in
larger samples. Regardless, the fact that being in the highest
ADHD PRS strata was associated with clinical severity, even
among referred youth, extends the rationale for considering
PRS as a tool for risk stratification in the clinical setting.
To confirm the potential value of genomic data for this
purpose, studies will need to document the longitudinal
outcomes of referred youth with high ADHD polygenic
burden and clarify the age of penetrance and potential
mediators of associated phenotypes. For example, though
ADHD onsets primarily in youth, prevention and inter-
vention strategies will depend on whether being at high risk
is associated with early and severe ADHD symptoms versus
their gradual unfolding. Moreover, the fact that the majority
of associations to phenotypes beyond ADHD remained
after controlling for the diagnosis suggests that simply
treating ADHD will not be sufficient for improving out-
comes in high-risk youth. Rather, genetically informed
prevention/early intervention programs that address specific
outcomes should be considered, and such efforts must be
appropriately timed. For instance, cost-effective targeting of
high-risk youth for educational supports and substance
prevention programs could be beneficial, but longitudinal
confirmation of our data would suggest that increased aca-
demic support is needed during an earlier developmental
window.
Limitations of our study should be acknowledged. First,
the trade-off for collecting a large clinical cohort in a cost-
efficient manner was a lack of structured diagnostic in-
terviews. Yet, several factors support the integrity of our
diagnoses. Our youth clinic is a training site at a teaching
hospital where attention is given to differential diagnosis.
Furthermore, k values from blinded ratings showed high
interclinician agreement, and we validated the ADHD
diagnosis, once made, with structured interviews in a subsetJournal of the American Academy of Child & Adolescent Psychiatry
Volume 59 / Number 8 / August 2020of patients. Furthermore, clinical diagnoses, though
imprecise, are the criterion most relevant to clinical trans-
lation,43 and analyses in adults conceptually replicated key
associations. Effect sizes for diagnoses in adults were slightly
lower than in youth; this was likely due to the wider variety
of clinicians and clinics from which they came and/or the
fact that ADHD in youths and adults shares some, but not
all, genetic underpinnings (see Faraone and Larsson21).
Despite these factors, the convergence of electronic health
record diagnostic codes with gold standard clinician ratings
has been established in this biobank previously for
ADHD44 and other conditions,45 and both adults and
youth with ADHD were included in the source GWAS.5
Thus, the significant results in our adult sample represent
an appropriate corroboration of primary findings.
Second, we cannot rule out the possibility that medica-
tion masked some variation in symptoms and test perfor-
mance, even after adjusting for covariates. Whereas a
medication-naïve sample would have been preferable, we did
not limit enrollment to preserve the generalizability of find-
ings. Similarly, we note that slightly more than half of the
youth in our sample had previously received treatment via
psychotherapy or medication. A source clinic such as ours,
which provides comprehensive neuropsychiatric evaluations
for purposes of differential diagnosis and school and treatment
planning, represents a setting in which genomic data would
be highly relevant. Thus, we included all consecutive referrals
to the clinic, regardless of treatment history. Third, we used
ASD PRS to address specificity/discriminant validity because
it related to a childhood-onset condition for which most of
our youth have passed through the age of risk. Nonetheless,
the discovery GWAS for ASD is small, and associations be-
tween ASD PRS and ADHD in our sample should be
revisited when the size of that GWAS increases. Fourth, as
discussed, we may have lacked statistical power to detect in-
teractions in our mixed effects models and thus cannot speak
to whether a high polygenic burden is characterized by greater
symptoms in specific psychopathology domains versus greater
symptoms more generally. Finally, we note that the current
analyses were limited to participants of European ancestries.
Translation to more racially and ethnically representative
samples is critical and will benefit from both statistical ad-
vances (eg, see Seldin et al.46) and collection of samples from
other populations (eg, see Dalvie et al.47).
Despite these issues, our results provide novel evidence
that ADHD PRSs are relevant to phenotypes that reflect the
broad ADHD construct among child psychiatric out-
patients. Additionally, a relatively high PRS burden in
outpatients is associated with greater clinical severity. It has
long been hoped that advances in genetics would have a
positive impact on child psychiatry,48 and data from recentwww.jaacap.org 975
VUIJK et al.GWASs are creating opportunities that have not previously
existed. The current findings help to advance the founda-
tional clinical science needed to translate ADHD PRSs to
clinical practice.
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